This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Case report
Hua Yang
The Fifth Affiliated Hospital of Sun Yat-sen University
Corresponding Author
ORCiD: https://orcid.org/0000-0002-7641-2031
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: The optimal management of Recurrent Ovarian granulosa cell tumors was still unknown, Hormone therapy maybe an alternative for chemotherapy-resistant cases. the reaction rate for aromatase inhibitors was highest, how to treat the progressed case after aromatase inhibitors was challenging.
Case presentation: Here we report a case of Recurrent Ovarian granulosa cell tumors treated with Diphereline and achieved clinical cure. A 46-year-old woman presented with third recurrence after primary treatment. She developed tumor progression and drug-induced nephritis after 6 cycles of combined treatment of cisplatin and paclitaxel for the second recurrence and failed to benefit from chemotherapy ,after the third Optimal cytoreduction and tumor progression after 6 months Letrozole treatent. The implementation of experimental treatment with Diphereline achieved Good therapeutic effect.
Conclusion: Hormone therapy maybe an alternative to recurrent granulosa cell tumors, Gonadotropin-releasing hormone agonistsas maybe a rescued treatment for Aroatase inhibitor-resistant cases
Keywords
gonadotropin-releasing hormone agonists(GnRHa), Hormone therapy, Recurrent adult Granulosa cell tumors.
Figure 1
Figure 2
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 08 Nov, 2021
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Oncology
Learn more about our company.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Case report
Hua Yang
The Fifth Affiliated Hospital of Sun Yat-sen University
Corresponding Author
ORCiD: https://orcid.org/0000-0002-7641-2031
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 08 Nov, 2021
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Oncology
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: The optimal management of Recurrent Ovarian granulosa cell tumors was still unknown, Hormone therapy maybe an alternative for chemotherapy-resistant cases. the reaction rate for aromatase inhibitors was highest, how to treat the progressed case after aromatase inhibitors was challenging.
Case presentation: Here we report a case of Recurrent Ovarian granulosa cell tumors treated with Diphereline and achieved clinical cure. A 46-year-old woman presented with third recurrence after primary treatment. She developed tumor progression and drug-induced nephritis after 6 cycles of combined treatment of cisplatin and paclitaxel for the second recurrence and failed to benefit from chemotherapy ,after the third Optimal cytoreduction and tumor progression after 6 months Letrozole treatent. The implementation of experimental treatment with Diphereline achieved Good therapeutic effect.
Conclusion: Hormone therapy maybe an alternative to recurrent granulosa cell tumors, Gonadotropin-releasing hormone agonistsas maybe a rescued treatment for Aroatase inhibitor-resistant cases
Figure 1
Figure 2
Loading...